Physician profile
Mohammad Ali
NPI 1699787341
$11,225.49
in general payments reported to CMS, 2019-2025
27 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,146 · 2020: $1,126 · 2021: $1,999 · 2022: $2,414 · 2023: $2,368 · 2024: $942 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,439 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,439.46 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,534.67 | 2019-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $3,311.00 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Genzyme Corporation | $1,011.42 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $563.38 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.59 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $401.52 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $181.98 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $163.93 | 2021-2022 | |
| Mylan Specialty L.P. | $162.81 | 2019-2020 | |
| Amgen INC. | $161.77 | 2021-2023 | Tezspire |
| Philips North America LLC | $155.54 | 2022-2024 | (Ak6) Vest Therapy |
| Boston Scientific Corporation | $139.45 | 2023 | |
| Pfizer INC. | $120.81 | 2019 | |
| Grifols USA, LLC | $119.38 | 2019-2024 | Gamunex-C |
| Novo Nordisk INC | $108.94 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $103.40 | 2025 | Ohtuvayre |
| Alkermes, INC. | $86.57 | 2024 | Vivitrol |
| Mdd US Operations, LLC | $72.89 | 2022-2024 | Gocovri, Gocovri |
| Advanced Respiratory, INC | $71.70 | 2019-2020 | |
| Abbott Laboratories | $48.43 | 2023 | Freestyle Libre 3 |
| Mallinckrodt Hospital Products INC. | $41.02 | 2021 | |
| Genentech USA, INC. | $38.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.28 | 2024 | Glassia |
| Circassia INC. | $25.19 | 2019 | |
| Baxter Healthcare | $16.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.59 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.